Key Highlights

  • Osteopore secured Thai market access for its full orthopaedic range, including its flagship product for medial opening wedge high tibial osteotomy.
  • DCH Auriga will act as market authorisation holder, importer and logistics partner in Thailand.
  • The company estimates an addressable segment of USD 60 to 80 million a year, and the next step is product listing in Bangkok hospitals, with no sales yet reported.

Osteopore Limited (ASX:OSX), an Australian-Singaporean regenerative medicine company with 3D-printed bioresorbable implants, announced on 9 September 2026 that it has secured market access in Thailand for the full range of its orthopaedic products.

Partnership structure

Osteopore has also secured its Supply chain and logistics network into Thailand through a Partnership with DCH Auriga, an Asia-based integrated market management provider specialising in healthcare. Auriga will be Osteopore's market authorisation holder, Import its devices into Thailand and supply hospitals and clinics as directed by Osteopore. Auriga operates in ten Asian markets, distributes more than 500 brands at over 10,000 points of sale and has a 50-year history.

Market size cited

The company cites a Datacube Research figure that the Thai orthopaedic devices market was valued at USD 749 million in 2025 and is projected to reach USD 1.5 billion by 2033, a compound annual growth rate of 9.2%. Bone-repair orthobiologics and bone graft substitutes typically represent around 8% to 10% of the market by value, and on that basis Osteopore estimates its addressable segment in Thailand at roughly USD 60 to 80 million a year. This is the company's own estimate and not a forecast of its sales.

Demand drivers described

Osteopore says Demand is supported by expanding access to reconstructive procedures under Thailand's universal healthcare coverage, a rising orthopaedic disease burden, and one of the world's highest road-trauma rates, which generates demand for materials that reconstruct bone defects from high-energy fractures.

Next steps and technology

The next step is product listing in target public and private hospitals in Bangkok. The release gives no timetable for listing, first orders or revenue. Osteopore says its patented scaffolds are made by 3D printing with a polymer that dissolves over time to allow natural bone tissue to form, reducing complications associated with permanent bone implants.

Osteopore's technology

Osteopore was founded in Singapore and is listed in Australia. It commercialises products designed to enable natural bone healing across several therapeutic areas, using patented micro-structured scaffolds produced by 3D printing in a bioresorbable polymer. The company says the polymer naturally dissolves over time, allowing natural bone tissue to form and reducing complications commonly associated with permanent bone implants.

The partner and what is unconfirmed

DCH Auriga was rebranded from LF Asia in 2017 and focuses exclusively on healthcare, connecting life sciences companies with care providers across Asia. The announcement does not provide pricing, Volume commitments, expected first orders or a time frame for hospital listings, so the commercial outcome in Thailand remains to be demonstrated.